Literature DB >> 11540865

d-Fenfluramine selectively suppresses carbohydrate snacking by obese subjects.

J Wurtman1, R Wurtman, S Mark, R Tsay, W Gilbert, J Growdon.   

Abstract

Twenty obese inpatients who claimed to crave carbohydrate-rich foods were given d-fenfluramine (15 mg p.o., twice daily) or its placebo, double-blind, for two consecutive eight-day periods. Food choices were measured on treatment days 1, 7, and 8 by giving the subjects access to unlimited portions of six isocaloric meal foods (three high in carbohydrate and three high in protein) and of 10 isocaloric snack foods (five high in protein and five high in carbohydrate) available 24 hours a day in a computerized vending machine. d-fenfluramine reduced mealtime calorie intake by only 16% (from 1940 +/- 94 to 1630 +/- 92; p < .001), mealtime carbohydrate by 22%, and had no significant effect on mealtime protein consumption; in contrast, snack calorie intake was reduced by 41% (from 707 +/- 97 to 414 +/- 46; p < .001), and snack carbohydrate intake by the same proportion. The mean number of carbohydrate-rich snacks consumed per day decreased from 5.8 +/- 0.8 to 3.4 +/- 0.4 (p < .01), while that of protein-rich snacks failed to change signficantly (i.e., from 0.7 +/- 0.2 to 0.5 +/- 0.2).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 11540865     DOI: 10.1002/1098-108x(198502)4:1<89::aid-eat2260040110>3.0.co;2-d

Source DB:  PubMed          Journal:  Int J Eat Disord        ISSN: 0276-3478            Impact factor:   4.861


  17 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Serotonergic drugs : effects on appetite expression and use for the treatment of obesity.

Authors:  Jason C G Halford; Joanne A Harrold; Emma J Boyland; Clare L Lawton; John E Blundell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Carbohydrate craving. Relationship between carbohydrate intake and disorders of mood.

Authors:  J J Wurtman
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 4.  Dexfenfluramine. Its place in weight control.

Authors:  P Turner
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 5.  The role of serotonin in eating disorders.

Authors:  S F Leibowitz
Journal:  Drugs       Date:  1990       Impact factor: 9.546

6.  The composition of lunch determines afternoon plasma tryptophan ratios in humans.

Authors:  H R Lieberman; B Caballero; N Finer
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

7.  Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients.

Authors:  V Ricca; E Mannucci; M Di Bernardo; S M Rizzello; P L Cabras; C M Rotella
Journal:  J Endocrinol Invest       Date:  1996-12       Impact factor: 4.256

8.  A comparison of the effects of d- and l-fenfluramine and d-amphetamine on energy and macronutrient intake in human subjects.

Authors:  E Goodall; S Feeney; J McGuirk; T Silverstone
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 9.  Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity.

Authors:  D McTavish; R C Heel
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

10.  Association of postpartum depression with weight retention 1 year after childbirth.

Authors:  Sharon J Herring; Janet W Rich-Edwards; Emily Oken; Sheryl L Rifas-Shiman; Ken P Kleinman; Matthew W Gillman
Journal:  Obesity (Silver Spring)       Date:  2008-03-27       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.